105 CMR 720.000: **DRUG FORMULARY COMMISSION** ~~LIST OF INTERCHANGEABLE DRUG PRODUCTS~~

Section
~~720.001: Purpose~~
~~720.002: Citation~~
~~720.010: Scope and Application~~
720.00**01**~~20~~: Definitions

~~Standards~~
720:040: Commission Review of ~~Relevant Drug Products~~ **Interchangeable Abuse-Deterrent Drug Products**
720.050: List of Interchangeable Drug Products
720.060: Drug Products Excluded **From the List of Interchangeable Drug Products**
720.070: **Formulary of Chemically Equivalent Substitutions for Opioids with Heightened Public Health Risk** ~~Amendments to the Massachusetts List of Interchangeable Drugs~~

~~Procedures for Amending List of Interchangeable Drug Products~~
720.080: Procedures for Amending the Massachusetts List of **Chemically Equivalent Substitutions for Opioids with Heightened Public Health Risk** ~~Interchangeable Drugs~~
~~720.081: Petition to Amend List of Interchangeable Drug Products~~
~~720.082: Commission Review of Petition~~
~~720.083: Notice of Public Comment Period~~
~~720.084: Commission Recommendation of Amendments to Department~~
~~720.090: Department Adoption of Amendments~~
720.100: Severability
~~720.200: Appendix A: List of Interchangeable Drugs~~

~~720.001: Purpose~~

~~The purpose of 105 CMR 720.000 is to establish a drug formulary, or list of interchangeable drug products, for use by physicians, other practitioners, and pharmacists licensed to practice within the commonwealth, so that consumers of prescription drug products may realize cost savings by buying less expensive, safe drug products.~~

~~720.002: Citation~~

~~105 CMR 720.000 shall be known as the 105 CMR 720.000: *Massachusetts List of Interchangeable Drug Products*.~~

~~720.010: Scope and Application~~

~~105 CMR 720.000 establishes the list of interchangeable drug products from which a pharmacist must interchange a reasonably available less expensive drug product than that written, when a prescription written by a practitioner indicates "interchange". 105 CMR 720.000 also establishes criteria and procedures for inclusion of drug products on this list.~~

720.00**01**~~20~~: Definitions

~~The terms used herein shall have the meanings set forth below. Terms defined in M.G.L. c. 112, § 12D and c. 94C, § 1, and not defined herein shall have the meanings set forth therein when used in 105 CMR 720.000, unless the context clearly requires a different interpretation.~~

~~Bioequivalent Drug Products means drug products whose rate and extent of absorption do not show a significant difference when administered at the same molar dose of therapeutic moiety under similar conditions. Some drug products may be equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered therapeutically equivalent because such differences in the rate of absorption are not essential to the attainment of effective body drug concentrations or are considered medically insignificant for the particular drug product studies.~~

~~Drug products for which bioequivalence is considered essential are those whose bioinequivalence would have therapeutic significance, i.e. use of different brands of the same drug product or different batches of the same drug product would result in therapeutic failure or a hazard to the patient. This is most critical in a drug product that has a narrow therapeutic-toxicity range which requires careful patient titration and monitoring for safe and effective use.~~

Abuse-deterrent property (ADP) means those properties of a drug formulation shown to meaningfully deter abuse, even if they do not fully prevent abuse.

ADP efficacy means the capacity of an abuse deterrent technology to produce the desired result of effectively deterring the abuse of an opioid with a heightened public health risk. There are three categories of ADP efficacy:

Category I: There is evidence, supported by scientifically sound outcome data, which demonstrates a reduction in the abuse of the product in the community setting compared to levels of abuse, overdose, and death that occurred when only formulations of the same opioid without abuse-deterrent properties were available.

Category II: Evidence is based on physical/chemical property, clinical abuse potential studies or laboratory manipulation studies and is not yet supported by scientifically sound outcome data which demonstrates a reduction in the abuse of the product in the community setting compared to levels of abuse, overdose, and death that occurred when only formulations of the same opioid without abuse-deterrent properties were available.

Category III: Evidence is based on physical/chemical property, theoretical assumptions or manufacturer's claims and is not yet supported by scientifically sound outcome data which demonstrates a reduction in the abuse of the product in

the community setting compared to levels of abuse, overdose, and death that occurred when only formulations of the same opioid without abuse-deterrent properties were available.

Chemically equivalent substitution means a drug product which contains the same active ingredients and is equivalent in strength or concentration, dosage form, and route of administration, and produces a comparable biologic effect as an opioid with heightened public health risk. Prodrugs or ingredients without analgesic effect that are used solely for abuse deterrent formulations need not be equivalent.

Commissioner means the commissioner of public health ~~appointed under M.G.L. c. 17, § 2.~~ **or his or her duly authorized agent.**

Department means the Department of Public Health ~~established under M.G.L. c. 17 as an agency within the Executive Department of the Commonwealth of Massachusetts~~.

Drug Product means a product which contains an active drug ingredient and is in a dosage form, e.g. tablet, capsule, or solution, generally, but not necessarily in combination with other substances included in the manufacturing process. An active drug ingredient is that portion of a drug product intended to produce a therapeutic effect.

Extended release (ER) means the drug product has a mechanism to prolong absorption of a drug to allow longer dosing intervals and to minimize fluctuations in serum drug levels.

FDA means the Food and Drug Administration of the United States Department of Health and Human Services.

Generic drug product means a drug product that is comparable to a brand or reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended use.

Generic name means a non-proprietary ~~(common)~~ name **given** ~~used~~ to ~~identify~~ a drug product**, pharmaceutical substance, or biologic product that may be used by all who wish to refer to this substance,** as listed by the United States Adopted Names Council and the United States Pharmacopeia in the USAN/USP Dictionary of Drug Names.

Immediate release (IR) means the active ingredient in the drug product is released within a small period of time, typically less than 30 minutes.

Interchangeable Drug Product means a product containing a drug in the same amounts of the same active ingredients in the same dosage form as other drug products with the same generic or chemical name.

Interchangeable abuse-deterrent (IAP) drug product means an opioid drug product that has either FDA-approved labeling for having abuse-deterrent properties or has manufacturer claims of abuse-deterrent properties and there is sufficient evidence of the efficacy of those abuse-deterrent properties.

Opioid means substances, both natural and synthetic, that act on opioid receptors to produce morphine-like effects, most often used medically to relieve pain. Opioids include opiates, an older term that refers to such drugs derived from opium, including morphine itself.

Opioids with a heightened public health risk (HPHR) means opioids that have an increased risk to the public health due to their potential for abuse and misuse.

Pharmaceutically equivalent drug products means drug products which contain the same active ingredients, and are identical in strength or concentration, dosage form, and route of administration.

Prodrug means a medication or compound, typically paired with a primary drug, that is converted within the body after administration into active form to improve (1) how a primary drug is absorbed, distributed, metabolized, and excreted, (2) the bioavailability of a poorly absorbed primary drug, or (3) the selective interaction with targeted cells or processes to reduce adverse or unintended effects of the primary drug, especially in treatments with severe side effects, like chemotherapy.

~~Public Health Council means the Department's governing body established under M.G.L. c. 17, § 3. See also M.G.L. c. 111, § 3.~~

Therapeutically equivalent drug products means drug products which are pharmaceutically equivalent; meet applicable standards for strength, quality, purity and identity; are bioequivalent in that: (a) they do not present a known or potential bioequivalence problem, and they do meet an acceptable in vitro standard; or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standards matching both rate and extent of absorption; are adequately labeled; and are manufactured in compliance with current Good Manufacturing Practice regulations.

720.040: Commission Review of **Interchangeable Abuse-Deterrent Drug Products** ~~Relevant Drug Products~~

~~In preparing the List of Interchangeable Drug Products and amendments thereto, the Drug Formulary Commission shall determine whether drug products meet the standards set forth in 105 CMR 720.050. In making this determination, the Commission shall assess and evaluate pertinent data, including, but not limited to, the United States Pharmacopeia and its supplements, additional pertinent listings of the FDA, other state formularies, formularies of various hospitals of the commonwealth, and data submitted by manufacturers and other interested persons, including chemical and laboratory listing~~

~~data and clinical evidence concerning bioequivalence and therapeutic equivalence where available. In reviewing this material, the Commission shall utilize the pharmaceutical and medical expertise of its members.~~

In preparing a drug formulary of chemically equivalent substitutions for opioids that have a heightened public health risk, the Drug Formulary Commission shall consider information contained in drug applications approved by the United States Food and Drug Administration and other regulatory and guidance documents distributed by the United States Food and Drug Administration. The commission shall consider: the accessibility of the drug and its proposed substitute; whether the drug's substitute is cost prohibitive; the effectiveness of the substitution; and whether, based upon the current patterns of abuse and misuse, the drug's substitute incorporates abuse deterrent technology that will be an effective deterrent to such abuse and misuse.

The formulary shall include formulations of drugs that the commission has determined may be appropriately substituted and that incorporate any of the following abuse deterrent properties:

(1) a physical or chemical barrier that (i) prevents chewing, crushing, cutting, grating, grinding, melting or other physical manipulations that enable abuse or (ii) resists extraction of the opioid by common solvents such as water, alcohol or other organic solvents;
(2) an agonist or antagonist combination that interferes with, reduces or defeats the euphoria associated with abuse;
(3) an aversion quality that produces an unpleasant effect if the dosage form is manipulated or altered or a higher dose than directed is used;
(4) a delivery system that, under United States Food and Drug Administration guidance, offers resistance to abuse;
(5) a prodrug technique that limits opioid activity until transformed in the gastrointestinal tract; or
(6) any other technique, as may be identified or recommended by the United States Food and Drug Administration, that offers significant abuse deterrence.

720.050: List of Interchangeable Drug Products

The Massachusetts List of Interchangeable Drug Products (MLID) shall consist of~~:~~

~~(1)~~ drug products which are considered by FDA to be therapeutically equivalent to other pharmaceutically equivalent products listed with the same generic or chemical name according to the most recent edition of "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements **(known as "The Orange Book")** as published by the United States Department of Health and Human Services:

~~(2) drug products specified on a list established by the Department and set forth in 105 CMR 720.200, for which the Commission has determined that the bioequivalence is not essential, or if the Commission has determined that the bioequivalence may be~~

~~essential, bioequivalence has been established. The list may include the following categories of drug products:~~

~~(a) drug products which hold New Drug Applications (NDAs) or Abbreviated New Drug Applications(ANDAs) approved by the FDA, which FDA does not consider to be therapeutically equivalent to other pharmaceutically equivalent products listed with the same generic or chemical name; and~~

~~(b) drug products exempt from the Food, Drug and Cosmetic Act of 1962, and included in the Drug Efficacy Study Implementation (DESI) done by the National Academy of Sciences/National Research Council; and~~

~~(c) frequently prescribed drug products which were manufactured prior to 1938 and meet the FDA Good Manufacturing Practices Requirements; and~~

~~(d) frequently prescribed over-the-counter drug products which contain the same amounts of active ingredients, in the same dosage forms, as other drug products with the same general or chemical name.~~

720.060: Drug Products Excluded **From the List of Interchangeable Drug Products**

The following categories of drug products are excluded from the list of interchangeable drug products:

(a) drug products for which ~~the Commonwealth has determined that~~ bioequivalence ~~may be~~ **is** essential, but for which bioequivalence has not been established **by the FDA**; and

(b) drug products which are the subject matter of patent rights issued by the U.S. Patent Office, for which provision by other than the patent-holder would violate the patent~~.; and~~

~~(c) drug products available from only one manufacturer at one price.~~

720.070: **Formulary of Chemically Equivalent Substitutions for Opioids with Heightened Public Health Risk**~~Amendments to the Massachusetts List of Interchangeable Drugs~~

~~(1) Drug products which meet the criteria specified in 105 CMR 720.050(1) shall be deemed interchangeable and added to the Massachusetts List of Drugs upon publication by the United States Department of Health and Human Services of the most recent edition of "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements.~~

~~(2) Drug products which meet criteria specified in 105 CMR 720.050(2) shall be deemed interchangeable and added to the Massachusetts List of Interchangeable Drugs in accordance with procedures set forth in 105 CMR 720.080.~~

The following chart provides the formulary of interchangeable abuse-deterrent drug products for opioids with a heightened public health risk. This formulary also lists approved interchangeable abuse-deterrent drug products that are not chemically equivalent substitutions for any opioids with heightened public health risk.

The chart includes the weight of evidence for each interchangeable abuse deterrent drug product's ADP Efficacy as one of the three categories of ADP efficacy.

HPHR Opioid	Interchangeable Abuse Deterrent Drug Product	Commercially Available Strengths	Dosing Frequency	ADP Efficacy Category
Kadian® (morphine ER capsules)	Embeda® (morphine sulfate ER/naltrexone capsule)	20 mg/0.8 mg	Every 24 hours or every 12 hours	Category II
Morphine ER 12 or 24 hour capsules (generic Kadian®)		30 mg/1.2 mg		
Morphine ER 24 hour capsules (generic Avinza®)		50 mg/2 mg		
Morphine ER tablet (generic MS Contin®)		60 mg/2.4 mg		
MS Contin® (morphine ER tablet)		80 mg/3.2 mg		
Zohydro ER® (hydrocodone ER capsule)	Hysingla ER® (hydrocodone ER tablet)	20 mg	Every 24 hours	Category II
		30 mg		
		40 mg		
		60 mg		
		80 mg		
		100 mg		
		120 mg		
No equivalent HPHR opioid identified	Nucynta ER® (tapentadol ER tablet)	50 mg	Every 12 hours	Category II
		100 mg		
		150 mg		

		200 mg 250 mg		
No equivalent HPHR opioid identified	Oxaydo® (oxycodone IR tablet)	5 mg 7.5 mg	Every 4-6 hours	Category III
No equivalent HPHR opioid identified	Oxycodone ER tablet	10 mg 15 mg 20 mg 30 mg 40 mg 60 mg 80 mg	Every 12 hours or every 8 hours	Category II
No equivalent HPHR opioid identified	OxyContin® (oxycodone ER tablet)	10 mg 15 mg 20 mg 30 mg 40 mg 60 mg 80 mg	Every 12 hours or every 8 hours	Category II
No equivalent HPHR opioid identified	Xtampza ER® (oxycodone ER capsule)	9 mg 13.5 mg 18 mg 27 mg 36 mg	Every 12 hours with food	Category II

The following chart lists the generic names of opioids with a heightened public health risk. If an HPHR opioid does not appear on the formulary of chemically equivalent substitutions for opioids with a heightened public health risk, no interchangeable abuse-deterrent drug product is available as a substitute at this time.

Schedule II Opioid Drug Products	**Schedule III Opioid Drug Products**
Generic Cross Reference Name	Generic Cross Reference Name
Oxycodone Hydrochloride	Buprenorphine/Naloxone
Acetaminophen/Oxycodone Hydrochloride	Acetaminophen/Codeine Phosphate
Acetaminophen/Hydrocodone Bitartrate	Buprenorphine Hydrochloride
Morphine Sulfate	Buprenorphine
Hydromorphone Hydrochloride	APAP/Butalbital/Caffeine/Codeine Phosphate
Fentanyl	Aspirin/Butalbital/Caffeine/Codeine Phosphate
Methadone Hydrochloride	Acetaminophen/Caffeine/Dihydrocodeine Bitartrate
Hydrocodone Bitartrate/Ibuprofen	Aspirin/Carisoprodol/Codeine Phosphate
Oxymorphone Hydrochloride	Aspirin/Caffeine/Dihydrocodeine Bitartrate
Tapentadol Hydrochloride	
Codeine Sulfate	
Meperidine Hydrochloride	
Levorphanol Tartrate	
Fentanyl Citrate	
Hydrocodone Bitartrate	
Aspirin/ Oxycodone Hydrochloride	
Morphine Sulfate/Naltrexone Hydrochloride	
Belladonna Alkaloids/Opium Alkaloids	
Ibuprofen/ Oxycodone Hydrochloride	

720.080: Procedures for Amending the Massachusetts List of **Chemically Equivalent Substitutions for Opioids with Heightened Public Health Risk** ~~Interchangeable Drugs~~

The Department, working with the Commission, shall review at least once a year and revise as necessary the ~~list of interchangeable drug products~~ **formulary of chemically equivalent substitutions for opioids with heightened public health risk provided in 105 CMR 720.070**~~adopted pursuant to 105 CMR 720.050(2)~~, and shall have the authority to review and revise the list ~~of interchangeable drug products~~ adopted pursuant to 105 CMR 720.0**70**~~50(1~~) as necessary. The revisions to 720.0**70**~~50(1~~) ~~shall be specified on an exception list established by the Department and set forth in 105 CMR 720.200. The revisions~~ will add and delete drug products, based on current information concerning **abuse deterrence** ~~therapeutic efficacy~~ and ~~interchangeability~~ **chemical equivalence** of drug products.

~~720.081: Petition to Amend List of Interchangeable Drug Products~~

~~Any person who desires a drug product or products to be added to or deleted from the List of Interchangeable Drug Products, shall file a written petition with the Department to amend the List, pursuant to M.G.L. c. 30A, § 4. Each petition shall be in such form as the Department may require and shall be submitted to the Drug Formulary Commission.~~

~~720.082: Commission Review of Petition~~

~~Upon receipt of a petition, the Department shall submit the petition and the supporting information to the Commission for review. The Commission shall make a preliminary determination whether the List of Interchangeable Drug Products should be amended as proposed.~~

~~720.083: Notice of Public Comment Period~~

~~Upon completion of the review of all relevant information, including petitions, by the Commission, the Department shall propose amendments to the List of Interchangeable Drug Products by issuing a Notice of Public Comment Period pursuant to M.G.L. c. 30A, §§ 2 and 3. The Department shall mail a Notice of Public Comment Period to each person who filed a petition during the period ending 30 days before the Notice of Public Comment Period is issued. In addition, the Department shall mail a Notice of the Public Comment Period to each person who has filed a written request therefore with the Department during December of the previous year pursuant to M.G.L. c. 30A, § 2.~~

~~720.084: Commission Recommendation of Amendments to Department~~

~~Following the comment period Department staff shall review all evidence and commentary concerning the proposed amendments, and shall report its recommendation to the Commission. The Commission shall consider the staff recommendations, make such revisions as it deems appropriate, and shall recommend Amendments to the List of Interchangeable Drug Products for adoption by the Commissioner and the Public Health Council.~~

~~720.090: Department Adoption of Amendments~~

The Commissioner and the Public Health Council shall consider the recommendations of the Drug Formulary Commission, and shall adopt Amendments to the List of Interchangeable Drug Products.

720.100: Severability

The provisions of 105 CMR 720.000 are severable. If any provision shall be declared invalid by any court, such provision shall be null and void and such determination shall not affect or impair any of the remaining provisions.

REGULATORY AUTHORITY 105 CMR 720.000: M.G.L. c. 17, § 13; c. 112, § 12D.

720.200: Appendix A

MASSACHUSETTS
LIST OF
INTERCHANGEABLE DRUGS

Department of Public Healthregulation105 CMR720.050 describes the *Massachusetts List of Interchangeable Drugs*.

105 CMR 720.050(a) calls for the automatic adoption of all "A" rated drug products listed in the "*Approved Drug Products with Therapeutic Equivalence Evaluations*" and its supplements as published by the U.S. Food and Drug Administration (FDA), Department of Health and Human Services. This publication is commonly referred to as the "*Orange Book*". It is reprinted by the U.S. Pharmacopeial Convention Inc. (USP) as *Volume III* of the *USP DI*.

105 CMR 720.050(b) allows for the establishment of the *Massachusetts Additional List of Interchangeable Drugs* (*Additional List*), and provides the criteria upon which these drug products are approved.

All prescriptions written by generic name can be interchanged if the drug is multi-source. To determine if a prescription written for a brand name drug product is interchangeable in Massachusetts:

1. Look up the drug product by the brand name in the index or by generic name in the "*Approved Drug Products with Therapeutic Equivalence Evaluations*" ("*Orange Book*"). The drug products are arranged alphabetically.
2. Compare the dosage form and strength of the drug product prescribed with the dosage form and strength of the same drug product in the "*Orange Book*".
3. If the same drug product, dosage form and strength has been assigned an "A" rating by FDA and is not listed on the *Exception List* contained within 105 CMR 720.050, the drug product is interchangeable.
4. If the drug product is not listed in the "*Orange Book*", refer to 105 CMR 720.050(b), the *Massachusetts Additional List of Interchangeable Drugs* (*Additional List*).
5. Look up the drug product by the generic name in the *Additional List*. The drug products are arranged alphabetically.

6. Compare the dosage form and strength of the drug product prescribed with the dosage form and strength of the same drug product listed on the *Additional List*.
7. If the same drug product, dosage form and strength are listed, the drug product is interchangeable.

Copies of the "*Approved Drug Products with Therapeutic Equivalence Evaluations*" and its supplements ("*Orange Book*") are available from the:

U.S. Food and Drug Administration
Department of Health and Human Services
Government Printing Office
Washington, D.C. 20402-9371
OPC 6768
(202) 783-3238
and www.fda.gov/cder/drug

Copies of the *USP DI* (third volume of *USP DI* is the "*Orange Book*") are available from:

The United States Pharmacopeial Convention, Inc.,
12601 Twinbrook Parkway
Rockville, MD 20852
(301) 881-0666

Copies of the *Massachusetts Additional List of Interchangeable Drug Products* (document number 105 CMR 720.000) are available from:

The State House Bookstore
Room 116
Boston, MA 02133
(617) 727-2834
and www.magnet.state.ma.us/dph/dcp/Drug Formulary/Drug Interchange

TABLE OF CONTENTS

FOREWORD

The *Massachusetts List of Interchangeable Drugs*, is prepared by the Drug Formulary Commission (DFC) and the Department of Public Health. The DFC is comprised of nine men and women appointed by the Governor for the express purpose of developing a list of those drug products that are safely interchangeable -- that is, equivalent to each other in all significant respects. The DFC was established by M.G.L. c. 17, § 13. This law was enacted with the intent of saving money for consumers of prescription drugs, since drug products that are marketed under trademark or proprietary names are often available in the generic forms from competing manufacturers at substantially lower prices. M.G.L. c. 112, § 12D mandates prescription forms that allow practitioners to prescribe interchangeable drug products by simply signing the signature line. If a practitioner determines that a brand name drug product should be dispensed, he/she must sign the signature line and write the words "**no substitution**" in his/her own handwriting in the space provided below the signature line.

The regulations call for the automatic adoption of "A" rated drug products listed in the "*Approved Drug Products with Therapeutic Equivalence Evaluations*" and its supplements (commonly referred to as the "*Orange Book*") as published by the U.S. Food and Drug Administration, Department of Health and Human Services, plus a list of additional drug products, the *Massachusetts Additional List of Interchangeable Drugs* ("*Additional List*"), individually reviewed and approved by the DFC and the Department. The regulations provide the criteria upon which the drug products listed on the *Additional List* are approved for interchange. The regulations also provide the DFC and the Department with the authority to review any "A" rated drug product listed in the "*Orange Book*" or drug product approved for interchange on the *Additional List* and delete it from the list of interchangeable drug products if deemed appropriate. Drug products assigned an "A" rating by FDA which are deleted from the Massachusetts *List* are

placed on the *Exception List*. Drug products listed on the *Additional List* which are subsequently deleted are removed from the *Additional List*.

Of the many factors considered by the Commission in determining which drugs to include on the *List*, equivalent safety and effectiveness are paramount. The Commission reviews evidence on bioequivalence and pharmaceutical equivalence and includes on the *List* only those drug products determined to be fully interchangeable and whose manufacturers are approved by the U.S. Food and Drug Administration. Practitioners may prescribe any drug that appears on the *List* with confidence that it is as safe and effective as its brand name counterpart.

The efforts of the Commission in the assessment and evaluation of data and the preparation of the *List* are to be commended. The Department presents the *Massachusetts List of Interchangeable Drugs* with pride and with confidence that the *List* will greatly benefit consumers throughout the Commonwealth.

INTRODUCTION

INTERCHANGEABLE (GENERIC) DRUG LAW

In 1976 the Massachusetts Legislature passed an Act Further Regulating the Establishment of a Formulary of Interchangeable Drug Products (St. 1976, c. 470, § 13), commonly known as the Generic Drug Law. This law, enacted to promote and regulate the use of generic drugs, created the Drug Formulary Commission to develop a list of interchangeable drug products and also required the use of a standard prescription form to encourage practitioners to prescribe generic drugs.

PRESCRIPTION FORM

M.G.L.c.112, § 12D mandates prescription forms with one signature line. If the prescriber signs the prescription form and writes the words "**no substitution**" in his/her own handwriting in the space provided below the signature line, the pharmacist must fill the prescription exactly as indicated, with no interchange permitted. However, if the prescriber signs the prescription and does not write "**no substitution**" under his/her signature, the pharmacist is legally required to dispense a less expensive, equivalent interchangeable drug product listed in the *Massachusetts List of Interchangeable Drugs* if one is reasonably available.

MASSACHUSETTS LIST OF INTERCHANGEABLE DRUGS

The *Massachusetts List of Interchangeable Drugs* (MLID) consists of the "A" rated drug products listed in the "*Approved Drug Products with Therapeutic Equivalence Evaluations*" and its supplements as published by the U.S. Food and Drug Administration, Department of Health and Human Services ("*Orange Book*") and the *Massachusetts Additional List of Interchangeable Drugs* (*Additional List*). The *Additional List* is developed by the Drug Formulary Commission. The Commission determines drug products to be interchangeable only when they meet certain criteria:

(a) the drug product is available from more than one source, with the same active ingredient in the same dosage form and strength;

(b) its manufacturer is approved by the U.S. Food and Drug Administration (FDA); and

(c) when essential to therapeutic outcome, the manufacturer of the drug has documented clinical evidence of bioequivalence.

The Commission judges that all the drugs included on the MLID meet these standards and are bioequivalent, if essential, based on assessment and evaluation of the U.S. Pharmacopeia and its supplements, other state and hospital formularies, listings of the U.S. Department of Health and Human Services of the FDA, and on the expertise of its members.

The *List* does not include:

(a) drugs that are protected by patent rights or available from only one source;

(b) many controlled-release and enteric coated drug products since they may not consistently deliver the same quantities of their active ingredients;

(c) those drugs for which the Commission had any significant doubt about safe interchange between manufacturers; and

(d) any drug for which bioequivalence is considered essential but for which bioequivalence has not been demonstrated or an appropriate standard for bioequivalence has not been established.

Bioequivalence is determined to be necessary for a particular drug when bioinequivalence might result in therapeutic failure or hazard to the patient. Bioequivalent drug products do not show a significant difference in the rate and extent of absorption when administered at the same dosage under similar conditions. Drugs that are equivalent in the extent to which they are absorbed into a patient's body that differ in the rate of absorption may be therapeutically equivalent -- having the same medical effect -- either because the rate of absorption is not essential to the attainment of effective body concentrations of the drug, or because the difference in the rate is otherwise considered medically insignificant. Bioequivalence is a primary consideration for those drug products with a narrow therapeutic/toxic dosage range (when variation in the rate or extent of absorption could have a critical effect) where careful determination of the correct dosage and monitoring of the patient is essential to safe and effective use. To determine for which drugs bioequivalence is essential, the Commission relies on expert medical testimony, studies done by the pharmaceutical industry, the knowledge and expertise of the individual members of the Commission, and advice from the FDA.

All drug products manufactured by FDA approved firms are considered safe and effective for their intended use, even if the product has not been included in the MLID. A practitioner may begin a patient's therapy with a drug product from any manufacturer who has been approved by the FDA, even though interchange of the drug once the dosage has been calculated for the individual is not advised.

Several generic drug products are manufactured under the same new drug application (NDA) as the brand name drug products. According to section 1.6 of the *Orange Book*, drug products with the same NDA are therapeutically equivalent. Massachusetts regulations allow the interchange of these products. Distributors or repackagers of drug products manufactured under the same NDA as the brand name product are not identified in the *Orange Book*. Pharmacists who may not be able to determine if drug products are interchangeable should contact the manufacturers, distributors or repackagers. In addition the Department maintains an unofficial list of these products.

Information relative to the Interchangeable (Generic) Drug Law may be obtained from the Department of Public Health, Division of Food and Drugs, 305 South Street, Jamaica Plain, MA 02130, telephone number (617) 727-2670, and from the Boards of Registration in Medicine, Dentistry and Pharmacy.

DRUG PRODUCT PROBLEM REPORTING INSTRUCTIONS

Since 1971 the United States Pharmacopeia (USP), in cooperation with various professional associations and the Food and Drug Administration (FDA), has operated the *Drug Product Problem Reporting Program*. This program can be utilized by pharmacists, physicians, or

consumers to report any product problems encountered when using drugs interchanged under the Massachusetts generic drug law. The program is product oriented, and patient identification not requested. Should you prefer to remain anonymous, so indicate to the USP and your name will be withheld from the manufacturer and the FDA. Your participation in reporting problems will help to ensure that the drug products prescribed and dispensed in Massachusetts are of continued high quality.

Reports should be sent to The United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, (301) 881-0666. The USP is an impartial, non-governmental organization concerned with drug standards and quality control. After USP receives a report, copies are forwarded to the FDA and to the manufacturer of the product involved. Either the FDA or the manufacturer may act to investigate or correct problems.

EXCEPTION LIST

Orange Book "A" rated drug products not approved for interchange.

There are currently no products designated to be listed on the Exception List.

ADDITIONAL LIST

The *Massachusetts Additional List of Interchangeable Drugs* (*Additional List*) has been printed in a format designed to be concise and understandable. Interchangeable drugs are listed alphabetically according to their official (chemical or generic) names, and separate sections in each listing show dosage forms, strengths, FDA approved manufacturers, and categories.

DRUG

Drugs are listed in alphabetical order by their generic names and are printed in capital letters. Drug products containing more than one active ingredient (for example, CODEINE PHOSPHATE, GUAIFENESIN) are listed in the conventional order of ingredients.

Only drug products grouped under single headings are to be interchanged.

DOSAGE FORM

Under the generic names are listed the various multisource dosage forms in which a drug product is available. Abbreviations used for dosage forms and approved manufacturers are found in the front of the *Additional List*.

Only identical dosage forms and strengths of identical drugs are to be interchanged.

STRENGTH

The approved strengths of the drug products are listed under the heading "Strength(s)." The "strengths" must be read along with the "dosage forms" since any strength shown is

available only for the dosage form directly to its left. Dosage strength is in metric units that are sometimes rounded off from apothecary measures, which may introduce slight variations in the strength of certain products. Single ingredient drug product strengths are separated by commas. Combination drug products have a slash separating the strengths of the individual ingredients. If more than one strength of a single component of a combination drug product is approved, they will be separated by commas. For example, the strength of a tablet of aspirin with codeine phosphate is "325mg / 15mg, 30mg, 60mg" which means that the combination is available with 325 milligrams of aspirin and 15, 30, or 60 milligrams of codeine phosphate. Drug products with three or more components have their active ingredients listed individually in parentheses and have slashes separating the strengths of the individual ingredients.

MANUFACTURERS

Next to the heading "Manufacturers" are all approved manufacturers for the drug product in that group, listed by three letter abbreviations in capital letters. (See list of manufacturer abbreviations in front of the *Additional List*.) Listed manufacturers have met all legal requirements, including compliance with the FDA Good Manufacturing Practices for the production of the drug product indicated. Approved manufacturers hold current new drug applications (NDAs) or abbreviated new drug applications (ANDAs) when required by law.

NDA, ANDA APPLICANT (NAME) CHANGES

Because it is not practical to identify in the *Massachusetts Additional List of Interchangeable Drugs* (*Additional List*) each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, these transfers and name changes are identified in this section. In addition, the new manufacturers are listed in parenthesis beside the original manufacturer under the *Manufacturers' Abbreviations* section of the *Additional List*. Where only partial approved product lines are transferred between applicants, each approved product involved will appear with the manufacturer name change in the *Additional List* amendment.

Previously listed name changes have been incorporated into the revised Manufacturers' Abbreviations section.

ABBREVIATIONS

The following abbreviations are used in the *Massachusetts List of Interchangeable Drugs*.

DOSAGE FORMS

aero	aerosol	ml	milliliter
amp	ampule	oint	ointment
cap	capsule	ophth	ophthalmic
conc	concentrate	oral gran	oral granules for reconstitution
e.c.	enteric-coated		
elix	elixir	oral powder	oral powder for reconstitution
g	gram		
Hbr	hydrobromide	oral sol	oral solution
HCl	hydrochloride	pow	powder
HC	hydrocortisone	sol	solution
inhl	inhalation	SR	sustained release
inhl liquid	inhalation liquid	subl tab	sublingual tablet
inhl sol	inhalation solution	supp	suppository
inj	injection	susp	suspension
irr sol	irrigating solution	syr	syrup
I.U.	international units	tab	tablet
liq	liquid	top aero	topical aerosol
lot	lotion	top swab	topical swab
mcg	microgram	U	units
mEq	milliequivalents	vag	vaginal
mg	milligram		

MANUFACTURER'S ABBREVIATIONS

3MP	3M Pharmaceutical
AAA	Alpha Therapeutic
ABB	Abbott
ABI	Abic
ABL	Able Laboratories
ACI	ACIC Limited
ACP	Advanced Care Prod.
ADV	Advanced Remedies
AGV	Agvar Chemicals
AKO	Akorn
AKZ	Akzona Inc.
ALC	Alcon Labs
ALL	Allergan Pharmaceuticals
ALI	Alliance Pharmaceutical
ALP	Alpharma
APP	Alphapharm Party
ALT	Altana
ALZ	Alza Corp.
ALR	Alra Laboratories
AMA	Amaric
AMB	Ambix Labs
ACC	American Cyanamid Co.
AHP	American Home Products
ARL	American Regent Labs.
AME	Amersham
AMG	Amgen
AMI	Amide Pharmaceuticals
AMT	American Therapeutics
ANA	Anabolic
ANB	Anbex
ANC	Angus Chemical
ANE	Anesta
ANG	Angelini
APO	Apothecon
APK	Apothekernes
APP	American Pharmaceutical Partners Inc.
ARC	Arcola Labs.
APC	Arcum Pharmaceuticlal Corp.
ARP	Armenpharm
ARM	Armour Pharmaceuticals
ASC	Ascot Hospital Products
ASA	Asta
ASP	Astra Pharmaceuticals LP
ATH	Athena Neurosciences
BAK	Baker Norton
BAN	Banner Pharmacaps
BAP	Barlan Pharmacal
B/I	Boehringer Ingelheim
B/M	Boehringer Mannheim. Ther. Div
BAR	Barr Labs
BAS	Basel Pharmaceuticals
BAT	Bartor
B&L	Bausch & Lomb
BAY	Bayer Corp
BEA	Beach Prod.
B-D	Becton,Dickinson & Co.
BED	Bedford Laboratories
BEL	Bell
BDP	Beta-Derm Pharmaceuticals
BER	Berlex
BFA	B.F. Asher
BHC	B.H. Chemicals
BID	Biodevelopment
BIO	Bio-Technology General
BIV	Biovail
BLA	Blairex Laboratories
BLO	Block Drug Co.
BLU	Bluline
BRL	Blue Ridge Laboratories
BOC	Bock Pharmacal
BOW	Bowman Pharm.
BMS	Bristol-Myers Squibb
BRC	Bracco Diagnostics
BRD	Bradley Pharm.
BRA	Braintree Laboratories
BRI	Bristol-Myers Prod.
BTG	BTG Pharmaceuticals
BVL	Ben-Venue Labs

BYR	Byron Chemical
C&M	C & M Pharmacal
CAD	Cadema Medical Products
CAG	Calgon Corp.
CDC	Carderm Capital
C-P	Chesebrough - Ponds
C-W	Cook - Waite
C/C	Chase Chemical
CSL	Chase Laboratories
C/P	Corvit Pharmaceuticals
CAL	Carlisle
CAM	Camall
CAR	Carnick Labs
CTW	CarterWallace
CEN	Century Pharmaceuticals
CBV	Cetus Ben Venue Therapeutics
CHA	Chamberlin Parenteral Corp.
CHE	Chelsea Laboratories
CHM	Chemed Corp.
CVO	Ciba Vision Ophthalmics
CIR	Circa Pharmaceuticals
CJD	Copanos, J.D.
CLA	Clay - Park
CLO	Clonmel Healthcare
CMB	C.M. Bundy
CMC	Consolidated Midland Corp.
C/T	Controlled Therapeutics
CMP	Carolina Medical Products
CNC	H.R. Cenci
COL	Colgate Palmolive
COM	Combe
CON	Connaught Laboratories
COO	Cooper Labs
COP	Copley Pharmaceutical
CPG	Consolidated Pharmacy Group
CRE	Creighton Products
CUM	Cumberland Swan
CUR	Curatex Pharmaceuticals
CTL	Central Pharmacal
D&G	Davis & Geck
D/L	DPT Laboratories
D-R	Del-Ray Laboratories Inc.
DAN	Danbury Pharmacal
DAR	Darby Group Companies
DEL	Dell
DEP	Deproco
DER	Dermik Laboratories
DES	Deseret Medical
DEY	Deylabs
DHL	DHL Laboratories
DIA	Dial Corp.
DIS	Dista
DMD	Duramed
DMG	D M Graham Laboratories
DOW	Dow Pharmaceutical
DPT	Dupont Pharmaceuticals
DPM	Dupont Merck
DUR	Dura Pharmaceuticals
DUN	Dunhall
DYN	Dynapharm
E/K	Eastman Kodak
EAT	Eaton Medical Corp.
ECR	ECR Pharmaceuticals
ELA	Elan Pharmaceuticals
ELL	Ellis Pharmaceuticals
EMP	EM Pharma
END	Endo
EON	Eon Laboratories
ENQ	Enquay Pharm
ENZ	Enzon
ESR	Ersana
ESI	ESI Lederle Generics
ESP	ESI Pharmacal
ETH	Ethicon Inc.
ETX	Ethex
ETK	Ethitek Pharmaceuticals
EVY	Everylife
EZC	E-Z-EM Co.
FAU	Faulding Pharm. Co.
FER	Ferndale
FRT	Ferrante
FRR	Ferring Labs
FIS	Fisons
FLE	Fleming & Co.
FOR	Forest
FOU	Fougera
FOY	Foy
FRE	Fresenius

G&W	G & W
GAL	Galderma
GEI	Geigy
GEC	Gencon
GED	Genderm
GET	Genentech
GEP	Genpharm
GEV	Geneva
GES	Gensia Sicor Pharmaceuticals Inc
GEZ	Genzyme
GIL	Gilbert Laboratories
GLD	Glades
GLW	GlaxoWellcome
GLE	Glenwood
GLO	Global Pharm.
G/P	Golden Pharms.
GOL	Goldine
GRE	Greenstone
GRI	Griffen,KW
G/L	Gruppo Lepetit
GUA	Guardian
GYM	GYMA Laboratories
GYN	Gynopharm
H-R	Holland-Rantos
HAL	Halsey Labs
HAM	Hamilton Pharmaceuticals
HAN	Hnford GC
HEA	Heather
HEN	Heran Pharmaceutical
HEX	Hexcel Chemical Products
HER	Hermal Pharmaceutical
HIC	Hickam
H/D	Hill Dermaceuticals
HIR	Hirsch Industries
HIT	Hi Tech Pharma
HTP	High Technology Pharmacal
HLC	Halocarbon
HCC	Hoechst Celanese Corp.
HMR	Hoechst Marion Roussell
HOE	Hoechst-Rousel
HOR	Horus Therapeutics
HOY	Hoyt
HUD	Hudson Pharmaceuticals
HUN	Huntington
HYB	Hybritec Inc.
HYG	Hygenics
HYR	Hyrex
IMM	Immunex
IMP	IMP Inc.
ICN	ICN Pharmaceuticals
IMS	International Medication
INP	Interpharm
INV	Invamed, Inc.
INW	Inwood Labs
ICC	Interchem Corp.
ILC	International Latex Corp.
ING	Ingram Pharmaceutical
INH	Inhalon
IOL	Iolab
IOM	Iomed
IPR	IPR Pharm
IVA	IVAX
J&J	Johnson & Johnson
JAC	Jacobus
JAN	Janssen Pharmaceuticals
JER	Jerome Stevens Labs
JRW	Johnson RW
JON	Jones Pharma Inc
KAL	Kalapharm
KBP	Kabi Pharmacia
KEE	Keene
KED	Kendall
KEN	Kenwood
KIN	King Pharmaceuticals
KIR	Kirkman Sales
KNO	Knoll
KPI	Key Pharmaceuticals
KVP	KV Pharmaceutical Co.
L/F	Labs Fournier
L/A	Laboratories Atral
LAF	Lafayette Pharms
LAN	Lannett
LED	Lederle
LEI	Leiras
LEK	Lek Ljubliana
LEM	Lemmon
LEO	Leo Pharms
LIF	Life Labs
LIL	Lilly
LIP	Liposome

LIQ	Liquipharm
LNK	LNK International
LOC	Loch Pharmaceuticals
LOR	Lorex
LOT	Lotus Biochemical
LPI	LPI Holding
LUI	Luitpold
LUS	Lek USA Inc.
LYN	LYNE Laboratories
M/P	Mallinckrodt Pharmaceutical.
MAY	Mayrand
MAT	Matrix Labs
MCG	Mcgaw
MCN	McNeil Consumer Products
MDP	MD Pharmaceuticals
MEA	Mead Johnson
MJN	Mead Johnson Nutritionals
M/R	Medco Research
MVA	Medeva
MEP	Medics Pharmaceuticals
MPI	Medi Physics, Inc.
MAG	Mepha AG
MER	Mericon
MET	Metronic
MGI	MGI Pharma
MID	Midway Medical
MIK	Mikart Laboratories
MIS	Mission Pharmacol
MJP	MJ Pharmaceuticals
MKL	Moore Kirk Labs
MLI	Marchar Laboratories
MLP	Miller Pharmacal
MLX	Milex
MMD	Marion Merrell Dow
MOR	Morton Grove
MCK	Merck & Co.
MSM	Marsam
MSL	Marshall Pharmacal
MTC	Martec
MOV	Mova
MUR	Muro
MUT	Mutual Pharmaceuticals
MYL	Mylan Pharmaceuticals
NEP	Nephron Pharmaceuticals Inc
NEU	Neutrogena
NOR	Norbrook Laboratories
N/W	Norton Waterford
N/N	Novo Nordisk
NEW	Newtron Pharmaceuticals
NHN	Norton HN
NOV	Novocol
NVP	Novopharm Ltd.
NUM	Numark
NYC	Nycomed
NYL	Nylos Trading
ORI	Organon, Inc.
OCL	Oclassen
OHM	OHM Laboratories
OMD	Ohmeda Pharmaceutical
OSA	On Site Azla
ODC	Ormont Drug & Chemical
OPC	Ortho Pharmaceuticals
OPT	Optopic Laboratories Corp.
ORG	Organics
OAP	Otsuka America Pharmaceutical
PAK	Pal Pak
PAL	Palisades
P/D	Parke Davis
P/I	Plantex/Ikpharm
P/K	Purepac Kalipharma
P/P	Parmed Pharmaceuticals
PAC	Paco Research
PAD	Paddock Labs
PHD	Pharmaderm
PAN	Panray
PAR	Par
PNL	Parnell
PER	Perrigo
PCE	Pharmachemie
PHC	Pharmics
PHK	Pharmakinetics Labs
PHM	Pharmeral
PHO	Phoenix Labs
PHS	Pharma Serve
PHT	Pharmaton
PFF	Pfeiffer
PFI	Pfizer
P/U	Pharmacia & Upjohn
P/A	Pharmaceutical Association
PIO	Pioneer Pharmaceutical Inc.

PPI	Physicians Products Inc.
PSA	Pharmaceutical Specialist Assoc
POH	Pohl Boskamp
POL	Polymedia
PGP	Prographarm
PRD	Professional Disposables
PRO	Proter Laboratory
PRI	Private Formulations
P&G	Proctor & Gamble
PRV	Pharmavite
PTK	Pharma-Tek
PUF	Purdue Frederick
PUR	Purepac
QUA	Quantum Pharmics Ltd.
QLT	QLT PhototherapeuticsInc.
RAN	Ranbaxy Pharmaceuticals
R/C	Reckitt & Colman
R&C	Reed & Carnrick
R/I	Research Industries
RXP	Rexar Pharmacal
RAC	Rachelle Labs
REN	Ren-Pharm Internatl. Ltd.
RHP	Rhone - Poulenc
RPR	Rhone-Poulenc Rorer
RAH	Robins, A.H.
REX	Rexall/Sundown
RIC	Richlyn Labs
ROC	Roche Labs.
RPF	Roerig/Pfizer
ROA	Roaco
RBP	Roberts Pharmaceutical
ROR	Rorer
ROS	Ross Labs
ROX	Roxane Labs
ROY	Royce Laboratories
RPC	Rosemont Pharmaceutical Corp.
RUG	Rugby Labs
S-M	Spencer-Mead
S/W	Sanofi Winthrop
S/L	Schmid Laboratories
SAK	Sankyo
SAV	Savage Labs/Altana
SAN	Sandoz
SCE	Scherer, R.P.
SPI	Schein Pharmaceutical, Inc.
SCH	Schering Corporation
S/P	Schering/Plough
SWZ	Schwarz Pharma
SZG	SchwarzGMBH
SCI	ScinoPharm International
SCS	SCS Pharmaceuticals
SEA	Searle
SER	Serono Laboratories
SEQ	Sequus Pharmaceuticals
SHM	Sherwood Medical
SHI	Shionogi USA
SID	Sidmak Laboratories
SIG	Sigma Tau
SIX	Silarx
SKB	Smith, Kline Beecham
SBH	Sola Barnes Hind
SOL	Solopak Laboratories
SLV	Solvay
SOM	Somerset
SBM	Sorin Biomedics
SDP	Sperti Drug Products
STI	Steifel
STL	Stanlabs Pharmaceutical Co.
STR	Star Pharmaceuticals
STS	Steris Laboratories
STZ	Storz Ophthalmics
SUP	Superpharm
SPP	Suppositoria
SUR	Survival Technology
SYN	Syntex
SYO	Syosset Labs
TAB	Tablicaps
TAG	Tag Pharmaceuticals
TAK	Takeda
TAP	Tap Holdings
TAR	Taro Pharmaceutical
TAY	Taylor Pharmaceuticals
TEC	Technilab
THE	Theratech
THK	Therakos
THA	Thames Phamacol Co. Inc.
TIC	Tican Pharmaceuticals
TOP	Topiderm
T/L	Torch Laboratories
TOR	Torigian Lab

~~UDL~~	~~UDL Laboratories~~
~~UMD~~	~~Unimed~~
~~UPJ~~	~~Upjohn~~
~~USL~~	~~Upsher-Smith Labs~~
~~VAL~~	~~Vale Chemical~~
~~VAN~~	~~Vangard~~
~~VES~~	~~Vestal~~
~~VIC~~	~~Vicks Pharmacy Products~~
~~VIN~~	~~Vintage~~
~~VIR~~	~~Viratek~~
~~VIS~~	~~Vistakon, Inc.~~
~~VIV~~	~~Vivan Pharmacal~~
~~W-A~~	~~Wyeth Ayerst~~
~~W-C~~	~~Warner-Chilcott~~
~~WAW~~	~~Warner Wellcome~~
~~WRR~~	~~Warrick Pharm~~
~~WEP~~	~~WE Pharmaceuticals~~
~~WEN~~	~~Wendt Laboratories~~
~~WPP~~	~~West Point Pharma~~
~~WES~~	~~Westwood Squibb Pharmaceuticals~~
~~W-W~~	~~West-Ward~~
~~W/L~~	~~Wharton Labs~~
~~WBY~~	~~Whitby~~
~~WWT~~	~~Whiteworth Towne~~
~~WAL~~	~~Wallace Labs~~
~~WAR~~	~~Warner-Lambert~~
~~WAT~~	~~Watson Laboratories~~
~~WOC~~	~~Wockhardt~~
~~XTT~~	~~Xttrium Laboratories~~
~~YAM~~	~~Yamanouchi~~
~~YOS~~	~~Yoshitomi Laboratories~~
~~ZCA~~	~~Zeneca~~
~~ZGP~~	~~Zenith Goldline Pharmaceuticals~~

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

AMINOPHYLLINE, EPHEDRINE Hcl Dosage form(s): TABLETS Strength(s): 130mg/25mg Manufacturers: STL Category: OTC
AMYL NITRITE Dosage form(s): INHALATION Strength(s): 0.3ml Manufacturers: GLW, CMC Category: PRE 38
ASPIRIN W/ CODEINE PHOSPHATE Dosage form(s): TABLET Strength(s): 325mg/15mg, 30mg, 60mg Manufacturers: BAR, GLW, CHE, GEV, HAL, P/D, ZGP Category: PRE 38
ATROPINE SULFATE Dosage form(s): OPHTHALMIC SOLUTION Strength(s): 0.5%, 1%, 2% OPHTHALMIC OINTMENT 0.5%, 1% Manufacturers: ALC, ALL, ESR, FOU, INV, MUR, B&L, STS, SUR Category: PRE 38
ATROPINE SULFATE COMPOUND (ATROPINE SULFATE, SCOPOLAMINE HBr, HYOSCYAMINE SULFATE, PHENOBARBITAL) Dosage form(s): TABLET Strength(s): 0.0194mg/0.0065mg/ 0 1037mg/16.2mg Manufacturers: ALL, CHE, M/P, MAY, TAY, RAH, WES Category: DESI
BENZOCAINE, ANTIPYRINE Dosage form(s): OTIC SOLUTION Strength(s): 1.4%, 5.4% Manufacturers: AMB, W-A, CLA, RPC, S-M, THA Category: PRE 38
BENZOYL PEROXIDE Dosage form(s): GEL Strength(s): 2.5%, 5%, 10% Manufacturers: BMS, CLA, GAL, STI, SYO, VIC, WES Category: OTC
BENZTHIAZIDE Dosage form(s): TABLET Strength(s): 50mg Manufacturers: GEV, PFI, RAH, Category: B
BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBr, PSEUDOEPHEDRINE HCl Dosage form(s): SYRUP Strength(s): 2mg/10mg/30mg/5ml Manufacturers: RAH, RPC Category: OTC
BROMPHENIRAMINE MALEATE, PHENYLPROPANOLAMINE HCl, PHENYLEPHRINE, GUAIFENESIN COMBINATION Dosage form(s): SYRUP Strength(s): 4mg/5mg/5mg/100mg/5ml

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

Manufacturers: HAL, LIF, RAH, RPC,	
Category: OTC	
CAFFEINE AND SODIUM BENZOATE	
Dosage form(s): INJECTION	Strength(s): 250mg/ml
Manufacturers: TAY	
Category: PRE 38	
CALCIUM GLUCONATE	
Dosage form(s): INJECTION	Strength(s): 10%
Manufacturers: ARL, APC, APP, CMC, CEN, BAY, ESR, GEN, HYR, KIR, LAN, LIL, M/P, P/D, RIC, STL, P/U ,	
Category: PRE 38	
CARBINOXAMINE MALEATE, PSEUDOEPHEDRINE HCl, DEXTROMETHORPHAN HBr	
Dosage form(s): DROPS	Strength(s): 2mg/25mg/4mg/ml
SYRUP	4mg/60mg/15mg/5ml
Manufacturers: ALP, ROS	
Category: PRE 38	
CHLORAL HYDRATE	
Dosage form(s): CAPSULE	Strength(s): 500mg
SYRUP	250mg/5ml, 500mg/5ml
Manufacturers: BMS, C/C, ALP, PHC, PUR, ROX, SCE, , ZEN	
Category: PRE 38	
CHLORDIAZEPOXIDE W/ CLIDINIUM BROMIDE	
Dosage form(s): CAPSULE	Strength(s): 5mg/2.5mg
Manufacturers: BAR, CHE, EON, GEV, HAL, ROC, LEM, PAR, QUA, ZGP	
Category: DESI	
CHLOROTHIAZIDE W/ RESERPINE	
Dosage form(s): TABLET	Strength(s): 250mg/0.125mg, 500mg/0.125mg
Manufacturers: MCK, MYL,	
Category: B	
CHLORPHENIRAMINE MALEATE	
Dosage form(s): TABLET	Strength(s): 4mg, 8mg, 12mg
SYRUP	2mg/5ml
Manufacturers: LAN, SCH	
Category: OTC	
CHOLINE MAGNESIUM TRISALICYLATE (CHOLINE SALICYLATE, MAGNESIUM SALICYLATE)	
Dosage form(s): TABLET	Strength(s): 500mg (=293mg/362mg), 750mg (=440mg/544mg), 1000mg (=587mg/725mg)
Manufacturers: PUF, SID	
Category: PRE 38	
CODEINE PHOSPHATE	
Dosage form(s): INJECTION	Strength(s): 15mg, 30mg, 60mg/ml

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

Manufacturers: ESR, KNO, STL, W-A	
Category: PRE-38	
CODEINE PHOSPHATE /GUAIFENESIN LIQUID	
Dosage form(s): LIQUID	Strength(s): 10mg/100mg/5ml
Manufacturers: RAH, HAL	
Category: PRE-38	
CYANOCOBALAMIN	
Dosage form(s): TABLET CAPSULE	Strength(s): 10mcg, 25mcg, 50mcg, 100mcg, 250mcg
Manufacturers: APP, BER, BMS, STS, DEL, ESR, INV, LEM, LIL, MMD, MCK, ALP, ORI, P/D, SAV, SOL, P/U, W-A	
Category: OTC	
CYCLANDELATE	
Dosage form(s): CAPSULE	Strength(s): 200mg/400mg
Manufacturers: CHE, GEV, DAN, FOR, INW, W-A, LAN, LEM, MDP, PAR, PIO, ZGP	
Category: DESI	
DEXAMETHASONE	
Dosage form(s): TABLET	Strength(s):0.25mg, 0.5mg, 0.75mg, 1.5mg, 4mg
Manufacturers: GEV, DAN, MCK, MYL, ORI, PAR, PRI, RIC, SLV, ROX, , USL	
Category: B	
DIETHYLPROPION HCl	
Dosage form(s): TABLET SUSTAINED RELEASE TABLET	Strength(s): 25mg 75mg
Manufacturers: CAM, , LEM, MMD, MDP, 3MP	
Category: B	
DIETHYLSTILBESTROL	
Dosage form(s): TABLET VAGINAL SUPPOSITORIES	Strength(s): 0.1mg, 0.5mg, 1.5mg
Manufacturers: BMS, LIL	
Category: B	
DIGOXIN	
Dosage form(s): TABLET	Strength(s): 0.125mg, 0.25mg, 0.5 mg
Manufacturers: GLW, AMI	
Category: PRE-38	
DIGOXIN	
Dosage form(s): INJECTION	Strength(s): 0.25mg/ml, 0.5mg/2ml
Manufacturers: GLW, ESR, EON, W-A	
Category: PRE-38	
DIMENHYDRINATE	
Dosage form(s): TABLET	Strength(s): 50mg
Manufacturers: ANA, STS, CHE, GEV, ESR, LEM, SEA, , W-A	

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

	Category: OTC	
DIPHENHYDRAMINE HCl		
	Dosage form(s): CAPSULE	Strength(s): 25mg, 50mg
	ELIXIR	12.5mg/5ml
	Manufacturers: HAL, ICN, P/D	
	Category: OTC	
DISULFIRAM		
	Dosage form(s): TABLET	Strength(s): 250mg, 500mg
	Manufacturers: W-A, DAN	
	Category: B	
EPINEPHRINE HCl		
	Dosage form(s): INJECTION	Strength(s): 0.01%, 0.1%
	OPHTHALMIC SOLUTION	0.1%, 0.25%, 0.5%, 1%, 2%
	Manufacturers: ABB, ALC, ALL, ARL, ESR,IMS, INV, LAN, P/D, W-A	
	Category: PRE-38	
ESTROGENS, ESTERIFIED		
	Dosage form(s): TABLET	Strength(s): 0.3mg, 0.625mg, 1.25mg, 2.5mg
	Manufacturers: BMS, PRI, SLV, SKB, SYN	
	Category: B	
ETHAVERINE HCl		
	Dosage form(s): CAPSULE	Strength(s): 100mg
	TABLET	
	Manufacturers: BFA, KEN, LEM, MEP	
	Category: PRE-38	
ETHINYL ESTRADIOL		
	Dosage form(s): TABLET	Strength(s): 0.02mg, 0.05mg
	Manufacturers: ORI, SCH, P/U	
	Category: B	
FLUOXYMESTERONE		
	Dosage form(s): TABLET	Strength(s): 2mg, 5mg, 10mg
	Manufacturers: BMS, RPC, P/U	
	Category: B	
GLYBURIDE		
	Dosage form(s): TABLET	Strength(s): 1.25mg, 2.5mg, 5mg
	Manufacturers: HOE, P/U	
	Category: B	
HYDRALAZINE HCl, HYDROCHLOROTHIAZIDE, RESERPINE		
	Dosage form(s): TABLET	Strength(s): 25mg/15mg/0.1mg
	Manufacturers: DAN, GEI, LEM	
	Category: B	
HYDROCHLOROTHIAZIDE W/ RESERPINE		
	Dosage form(s): TABLET	Strength(s): 25mg/0.125mg, 50mg/0.125mg,

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

	25mg/0.1mg, 50mg/0.1mg
	Manufacturers: KNO, CAM, GEI, GEV, DAN, LEM, MCK, PUR, ZGP
	Category: B
HYDROCODONE BITARTRATE W/ PHENYLPROPANOLAMINE	
Dosage form(s): SYRUP	Strength(s): 5mg/25mg/5ml
Manufacturers: DPT, ALP, RPC	
Category: OTHER	
HYDROCORTISONE, IODOCHLORHYDROXYQUIN	
Dosage form(s): CREAM OINTMENT	Strength(s): 0.5%, 1% / 3%
Manufacturers: AMB, ALT, CLA, DER, BAY, DUR, GEI, LEM, ALP, SLV, THA,	
Category: DESI	
HYDROFLUMETHIAZIDE, RESERPINE	
Dosage form(s): TABLET	Strength(s): 25mg, 50mg/0.125mg
Manufacturers: APO, RPC, ZGP	
Category: B	
HYDROQUINONE 4% CREAM	
Dosage form(s): TOPICAL CREAM	Strength(s): 4%
Manufacturers: ICN, ETX	
Category: PRE 62	
HYDROQUINONE CREAM 4%	
Dosage form(s): CREAM	Strength(s): 4%
Manufacturers: ICN; GLD	
Category: PRE 1962	
HYDROQUINONE 4% CREAM with SUNCREENS	
Dosage form(s): TOPICAL CREAM	Strength(s): 4%
Manufacturers: ICN, ETX	
Category: PRE 62	
HYDROQUINONE CREAM 4% with SUNCREEN	
Dosage form(s): CREAM	Strength(s): 4%
Manufacturers: ICN; GLD	
Category: PRE 1962	
HYDROQUINONE TOPICAL SOLUTION	
Dosage form(s): TOPICAL SOLUTION	Strength(s): 3%
Manufacturers: NEU, GLD	
Category: PRE 38	

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

ISOSORBIDE DINITRATE Dosage form(s): SUSTAINED RELEASE CAPSULE Strength(s): 40mg Manufacturers: ASC, GEV, FOR, W-A, SUP Category: B
ISOXSUPRINE HCl Dosage form(s): TABLET Strength(s): 10mg, 20mg Manufacturers: GEV, MEA Category: PRE-38
L-HYOSCYAMINE SULFATE Dosage form(s): TABLET Strength(s): 0.125mg Manufacturers: BFA, GLW, SWZ Category: PRE-38
LEVODOPA Dosage form(s): TABLET Strength(s): 250mg, 500mg CAPSULE 100, 250, 500mg Manufacturers: ROC, P&G Category: B
MAGNESIUM SALICYLATE Dosage form(s): TABLET Strength(s): 600mg Manufacturers: BFA, END, RBP, MLP, , Category: OTHER
MAGNESIUM SULFATE Dosage form(s): INJECTION Strength(s): 10%, 12.5%, 50% Manufacturers: ABB, APP, ARL, CMC, ESR, IMS, LIL Category: PRE-38
MAZINDOL Dosage form(s): TABLET Strength(s): 1mg Manufacturers: SAN, W-A Category: B
MEPHOBARBITAL Dosage form(s): TABLET Strength(s): 32mg, 100mg, 200mg Manufacturers: BOW, ICN, S/W Category: PRE-38
METHENAMINE MANDELATE Dosage form(s): SUSPENSION Strength(s): 0.25, 0.5g/5ml TABLET 0.25g, 0.5g, 1g ENTERIC COATED TABLET 0.25g, 0.5g, 1g Manufacturers: GEV, HEA, ALP, P/D, RIC, SLV, TAB Category: PRE-38
METHENAMINE COMBINATION (METHENAMINE, PHENYLSALICYLATE, ATROPINE SULFATE, HYOSCYAMINE, BENZOIC ACID, METHYLENE BLUE)

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

	Dosage form(s): TABLET	Strength(s): 40.8mg/18mg/0.03mg/ 0.03mg/4.5mg/5.4mg
	Manufacturers: CHE, LEM, , S M, STR	
	Category: DESI	
METHYLENE BLUE		
	Dosage form(s): INJECTION	Strength(s): 1%
	TABLET	
	Manufacturers: ARL, CMC, ESR, TAY,	
	Category: PRE 38	
METHYLTESTOSTERONE		
	Dosage form(s): CAPSULE	Strength(s): 10mg
	SUBL. TABLET	10mg, 25mg
	Manufacturers: DAN, INW, LAN, PUR, SCH	
	Category: B	
MORPHINE SULFATE		
	Dosage form(s): SUSTAINED RELEASE TABLET	Strength(s): 30mg, 60mg, 100mg
	Manufacturers: PUF, ROX	
	Category: B	
NEOSTIGMINE METHYLSULFATE		
	Dosage form(s): INJECTION	Strength(s): 1-1000, 1-2000, 1-4000
	Manufacturers: CMC, ESR, LAN, S M,	
	Category: PRE 38	
NITROGLYCERIN		
	Dosage form(s): SUBLINGUAL TABLET	Strength(s): 0.3mg, 0.4mg, 0.6mg
	Manufacturers: P/D ETX	
	Category: PRE 38	
NORTRIPTYLINE HCl		
	Dosage form(s): CAPSULE	Strength(s): 10mg, 25mg
	Manufacturers: LIL, SAN	
	Category: B	
NYLIDRIN		
	Dosage form(s): TABLET	Strength(s): 6mg, 12mg
	Manufacturers: GEV, C/P, DAN, ROR, ZGP	
	Category: DESI	
OPIUM TINCTURE, DEODORIZED		
	Dosage form(s): LIQUID	Strength(s): 10% OPIUM
	Manufacturers: HAL, LIL	
	Category: PRE 38	
PAPAVERINE HCl (NON-SUSTAINED RELEASE)		
	Dosage form(s): INJECTION	Strength(s): 30mg/ml
	CAPSULE	75mg, 150mg, 300mg
	TABLET	30mg, 60mg, 100mg, 150mg, 200mg, 300mg

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

	Manufacturers: CHE, CMC, GEV, DAN, HAL, HEA, LAN, LEM, MMD, MYL, PUR, REN, SLV, VAN, EON, ZGP Category: PRE 38
PARALDEHYDE	
	Dosage form(s): LIQUID — Strength(s): 100% INJECTION Manufacturers: CMC, ESR, Category: PRE 38
PAREGORIC	
	Dosage form(s): LIQUID — Strength(s): 2mg MORPHINE EQUIV./5ml Manufacturers: APC, BOW, HAL, LAN, LIL, ALP, P/D, PUR, ROX, RPC, STL Category: OTC
PENICILLIN G BENZATHINE	
	Dosage form(s): INJECTION — Strength(s): 600, 000 UNITS/ml Manufacturers: PFI, W-A Category: B
PENTAERYTHRITOL TETRANITRATE	
	Dosage form(s): TABLET — Strength(s): 10, 20 SUSTAINED ACTION TABLET — 80mg Manufacturers: COO, GEV, DAN, INW, KIR, MER, P/D, PUR, STA, S-M, ZGP Category: DESI
PHENAZOPYRIDINE HCl	
	Dosage form(s): TABLET — Strength(s): 100mg, 200mg Manufacturers: AMI, BAR, COP, C-P, LAN, P/D, QUA, RIC, S-M, TAB, VAN, Category: PRE 38
PHENOBARBITAL	
	Dosage form(s): ELIXIR — Strength(s): 20mg/5ml TABLET — 15mg, 16mg, 30mg, 32mg, 60mg, 65mg, 100mg Manufacturers: APC, BAR, BOW, GEV, C/P, DAN, HAL, ICN, INW, LAN, LED, LEM, LIL, MMD, ALP, P/D, PUR, REX, ROX, RUG, STL, STA, TAB, EON, W-W, S/W, W-A, ZGP Category: PRE 38
PHENYLEPHRINE HCl	
	Dosage form(s): SOLUTION — Strength(s): 0.25%, 1% OPHTHALMIC SOLUTION — 0.12, 2.5, 10% Manufacturers: AKO, ALC, ALL, ALP, MUR, B&L, PUF, RPC, STS, S/W Category: PRE 38
PHENYLPROPANOLAMINE HCl, PHENYLEPHRINE HCl, PHENYLTOLOXAMINE CITRATE, CHLORPHENIRAMINE MALEATE	
	Dosage form(s): PEDIATRIC DROPS — Strength(s): 5mg/1.25mg/2mg/0.5mg/ml PEDIATRIC SYRUP — 5mg/1.25mg/2mg/0.5mg/5ml Manufacturers: ALP, APO Category: PRE 38

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

PHYTONADIONE		
Dosage form(s):	INJECTION	Strength(s): 2mg, 10mg/ml
Manufacturers:	ABB, ROC, IMS, MCK, SKB	
Category:	B	
PILOCARPINE HCl		
Dosage form(s):	OPHTHALMIC SOLUTION	Strength(s): 0.25%, 0.5%, 1%, 2%, 3%, 4%, 6%, 8%
Manufacturers:	ALC, CVO, W-A, OPT, B&L, PRO, STS	
Category:	PRE 38	
PIPERAZINE CITRATE		
Dosage form(s):	SYRUP	Strength(s): 500mg/5ml
	TABLET	250mg, 500mg
Manufacturers:	BLU,ALP, GLW, LAN, SLV, S/W	
Category:	PRE 38	
POTASSIUM GLUCONATE		
Dosage form(s):	LIQUID	Strength(s): 20mEq/15ml
Manufacturers:	ALP, CMC, GEV, LAN, LED, , RAH, ROX, RPC, S M,	
Category:	B	
POTASSIUM IODIDE		
Dosage form(s):	LIQUID	Strength(s): SATURATED SOLUTION
Manufacturers:	ALP, CMC, GEN, GEV, P/R, ROX, RPC, STL, , USL	
Category:	PRE 38	
PREDNISOLONE ACETATE		
Dosage form(s):	INJECTION	Strength(s): 25, 50, 100mg/ml
Manufacturers:	ALC, ALL, CTL, STS, LEM, B&L, SCH	
Category:	B	
PREDNISOLONE TEBUTATE		
Dosage form(s):	INJECTION	Strength(s): 20mg/ml
Manufacturers:	ALP, FOY, RBP, MCK	
Category:	B	
PROBENECID W/ COLCHICINE		
Dosage form(s):	TABLET	Strength(s): 500mg/0.5mg
Manufacturers:	DAN, LEM, MCK, RIC, ZGP	
Category:	B	
PROMETHAZINE HCl		
Dosage form(s):	TABLET	Strength(s): 12.5mg, 25mg, 50mg
Manufacturers:	ALL, ALT, ALP, DAN, ESR, GEV, KNO, KVN, LEM, LIF, MSM, RPC, S/W, W-A	
Category:	B	
PROPYLTHIOURACIL		
Dosage form(s):	TABLET	Strength(s): 50mg
Manufacturers:	ANA, KNO, CHE, DAN, LIL, HAL, LAN, LED, P/D, PUR, RIC, TAB, W-W, ZEN	
Category:	B	

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

PSEUDOEPHEDRINE HCl		
Dosage form(s):	LIQUID	Strength(s): 30mg/5ml
	TABLET	30mg, 60mg
	SUSTAINED RELEASE CAPSULE	120mg
Manufacturers:	ALP, BOW, GLW, CEN, CHE, GEV, DAN, HAL, RBP, LEM, MMD, PAR, ROX, SLV, SUP	
Category:	OTC	
PSEUDOEPHEDRINE HCl, CHLORPHENIRAMINE MALEATE		
Dosage form(s):	TABLET	Strength(s): 60mg/4mg
Manufacturers:	BER, GLW, ROR, SCH, SKB	
Category:	OTC	
PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE		
Dosage form(s):	SUSTAINED RELEASE TABLET	Strength(s): 120mg/6mg
Manufacturers:	COP, GEV, SCH	
Category:	OTC	
QUININE SULFATE		
Dosage form(s):	TABLET	Strength(s): 260mg
Manufacturers:	CHE, GEV, MMD	
Category:	PRE 38	
RAUWOLFIA SERPENTINA		
Dosage form(s):	TABLET	Strength(s): 50mg, 100mg
Manufacturers:	BOW, CMB, GEV, DAN, FER, HAL, ICN, KIR, PAN, PPI, PRI, BMS, SLV, RIC, TAB, VAL, ZEN	
Category:	B	
RESERPINE		
Dosage form(s):	TABLET	Strength(s): 0.1mg, 0.25mg, 0.5mg, 1.0mg
	INJECTION	
Manufacturers:	BEL, BMS, BOW, CMB, GEV, DAN, FER, GEI, GEN, HAL, ICN, , KIR, LAN, LEM, LIL, MKL, MYL, PAN, PRV, PRI, PUR, SLV, REX, RIC, ROX, STL, TAB, P/U, VAL, ZEN	
Category:	B	
SALSALATE		
Dosage form(s):	TABLET	Strength(s): 500mg, 750mg
Manufacturers:	GEV, 3MP, SID	
Category:	Pre 38	
SODIUM FLUORIDE		
Dosage form(s):	TABLET	Strength(s): 0.55mg, 1.1mg, 2.2mg (NaF)
	DROPS	0.125mg (F)/DROP
	CHEWABLE TABLET	0.55mg, 1.1mg, 2.2mg (NaF)
Manufacturers:	ABL, KNO, BOW, CHE, CMC, COP, C P, GEN, HOY, KIR, RIC, RUG, STL,	
Category:	PRE 38	

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

SULFAMETHOXAZOLE, PHENAZOPYRIDINE HCl		
Dosage form(s): TABLET	Strength(s): 500/100mg	
Manufacturers: COP, RIC		
Category: DESI		
SULFASALAZINE		
Dosage form(s): ENTERIC COATED TABLETS	Strength(s): 500mg	
Manufacturers: DAN, LED, LEM, MUT, KBP, ROW, SUP, VIP		
Category: B		
SULFISOXAZOLE PHENAZOPYRIDINE HCl		
Dosage form(s): TABLET	Strength(s): 500/50mg	
Manufacturers: COP, KAY, ROC, ROX, SLV, S-M, STN, VAN,		
Category: DESI		
TERBUTALINE SULFATE		
Dosage form(s): TABLET	Strength(s): 2.5mg, 5mg	
Manufacturers: GEI, MMD		
Category: B		
TESTOSTERONE		
Dosage form(s): INJECTION	Strength(s): 25mg/ml, 50mg/ml, 100mg/ml	
Manufacturers: BAT, STS,RBP, LIL, MAY		
Category: PRE 38		
TETRACAINE HCl		
Dosage form(s): OPHTHALMIC SOLUTION	Strength(s): 0.5%	
Manufacturers: ALC, GEN, B&L, S-M, S/W		
Category: PRE 38		
THEOPHYLLINE (NON-SUSTAINED RELEASE)		
Dosage form(s): CAPSULE	Strength(s): 100mg, 200mg	
TABLET	100, 125, 200, 225, 250mg	
Manufacturers: ALP, BEL, BER, CNC, CTL, FER, HAL, KNO, LAN, LIF, MMD, PAN, P/A, RIC, 3MP, ROR, ROX, RPC, SEA,		
Category: B		
THEOPHYLLINE, GUAIFENESIN		
Dosage form(s): ELIXIR	Strength(s): 150mg/90mg/15ml	
LIQUID		
Manufacturers: MEA, RPC		
Category: PRE 38		
THEOPHYLLINE, POTASSIUM IODIDE (THEOPHYLLINE, POTASSIUM IODIDE, ALCOHOL)		
Dosage form(s): ELIXIR	Strength(s): 80mg/130mg/10%/15ml	
Manufacturers: FOR, ALP, RPC		
Category: PRE 38		
THYROGLOBULIN		
Dosage form(s): TABLET	Strength(s): 65mg	
Manufacturers: RIC, P/D, W-L		

~~MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS~~

~~Category: B~~
~~TRIAMCINOLONE DIACETATE~~ ~~Dosage form(s): INJECTION Strength(s): 25mg, 40mg/ml~~ ~~Manufacturers: BMS, LED, LEM, STS~~ ~~Category: B~~
~~TRICHLORMETHIAZIDE, RESERPINE~~ ~~Dosage form(s): TABLET Strength(s): 4mg/0.1mg~~ ~~Manufacturers: MMD, SCH~~ ~~Category: B~~
~~TRIPROLIDINE HCl, PSEUDOEPHEDRINE HCl~~ ~~Dosage form(s): TABLET Strength(s): 2.5mg/60mg~~ ~~SYRUP 1.25mg/30mg/5ml~~ ~~Manufacturers: GLW, ALP, CHE, CNC, GEV, HAL, ICN, LED, LEM, LIF, NEW, B&L, PRI, PUR, ROX, SLV, SUP, VAN, ZEN~~ ~~Category: OTC~~
~~TRYPSIN, BALSAM PERU, CASTOR OIL~~ ~~Dosage form(s): TOPICAL AEROSOL Strength(s): 0.1mg/72.5mg/650mg IN EACH 0.82CC SPRAY~~ ~~Manufacturers: COP, HIC~~ ~~Category: PRE 38~~

PARTIAL PROPRIETARY BRAND CROSS-REFEREN REFERENCE

Generically equivalent drug products in the same strength and dosage form listed in the *Additional List* are interchangeable if their respective manufacturers are listed for that product. This partial cross-reference section does not attempt to list all brand names which are approved for interchange. For most products only one, usually the innovator or most commonly prescribed brand, is listed below for quick reference purposes.

See page 4105 for precise instructions for determining the interchangeability of drug products.

BRAND — **SEE**

(ATROPINE SULFATE, HYOSCINE HBr, HYOSCYAMINE HBr, PHENOBARBITAL)

(THEOPHYLLINE, POTASSIUM IODIDE, ALCOHOL)

ACTIFED ..... TRIPROLIDINE HCl, PSEUDOEPHEDRINE HCl

ANDROID ..... METHYLTESTOSTERONE

ANTABUSE DISULFIRAM

AQUAMEPHYTON ..... PHYTONADIONE

AURALGAN ..... BENZOCAINE, ANTIPYRINE

AZO GANTANOL ..... SULFAMETHOXAZOLE, PHENAZOPYRIDINE

AZO GANTRISIN ..... SULFISOXAZOLE PHENAZOPYRIDINE HCl

AZULFADINE ..... SULFASALAZINE

BENADRYL ..... DIPHENHYDRAMINE HCl

CYANOCOBALAMIN

BICILLIN ..... PENICILLIN G BENZATHINE

BRETHINE ..... TERBUTALINE SULFATE

CHLOR TRIMETON ..... CHLORPHENIRAMINE MALEATE

COL BENEMID ..... PROBENECID W/ COLCHICINE

CYCLANDELATE

DECADRON ..... DEXAMETHASONE

DESQUAM ..... BENZOYL PEROXIDE

DIMETANE DX ..... BROMPHENIRAMINE, DEXTROMETHORPHAN, PSEUDOEPHEDRINE

DIUPRESS ..... CHLOROTHIAZIDE W/ RESERPINE

DONNATAL ..... ATROPINE SULFATE COMPOUND

DRAMAMINE ..... DIMENHYDRINATE

DRIXORAL ..... (product reformulated)

ECONOPRED ..... PREDNISOLONE ACETATE

ELIXOPHYLLINE KI ..... THEOPHYLLINE, POTASSIUM IODIDE

EMPIRIN W/ CODEINE ..... ASPIRIN W/ CODEINE PHOSPHATE

ESTINYL ..... ETHINYL ESTRADIOL

EXNA ..... BENZTHIAZIDE

FEDAHIST ..... PSEUDOEPHEDRINE HCl, CHLORPHENIRAMINE MALEATE

GLAUCON ..... EPINEPHRINE HCl

GRANULEX ..... TRYPSIN, BALSAM PERU, CASTOR OIL

HALOTESTIN ..... FLUOX\YMESTERONE

HYCOMINE ..... HYDROCODONE BITARTRATE W/ PHENYLPROPANOLAMINE

HYDROPRES ..... HYDROCHLOROTHIAZIDE W/ RESERPINE

ISOPTO CARPINE ..... PILOCARPINE HCl

ISORDIL TEMBID ..... ISOSORBIDE DINITRATE

ISUPREL ..... ISOPROTERENOL HCl

BRAND	SEE
KAON	POTASSIUM GLUCONATE
KENALOG	TRIAMCINOLONE DIACETATE
LARODOPA	LEVODOPA
LEVSIN	L-HYOSCYAMINE SULFATE
LIBRAX	CHLORDIAZEPOXIDE W/CLIDINIUM BROMIDE
MANDELAMINE	METHENAMINE MANDELATE
MEBARAL	MEPHOBARBITAL
MENEST	ESTROGENS, ESTERIFIED
METALONE T.B.A	PREDNISOLONE TEBUTATE
MICRONASE	GLYBURIDE
MAGNESIUM SALICYLATE	
NEO-SYNEPHRINE	PHENYLEPHRINE HCl
CHLORAL HYDRATE	
PAMELOR	NORTRIPTYLINE HCl
PHENERGAN PLAIN	PROMETHAZINE HCl
PONTOCAINE	TETRACAINE HCl
PROSED	METHENAMINE COMBINATION (METHENAMINE, PHENYLSALICYLATE, ATROPINE SULFATE, HYOSCYAMINE, BENZOIC ACID METHYLENE BLUE)
PROSTIGMINE	NEOSTIGMINE METHYLSULFATE
PYRIDIUM	PHENAZOPYRIDINE HCl
QUINAMM	QUININE SULFATE
SALUTENSIN	HYDROFLUMETHIAZIDE, RESERPINE
SANOREX	MAZINDOL
SERAPES	HYDRALAZINE HCl, HYDROCHLOROTHIAZIDE, RESERPINE
SLO-PHYLLIN GG	THEOPHYLLINE, GUAIFENESIN
SLO-PHYLLIN	THEOPHYLLINE (NON-SUSTAINED RELEASE)
SSKI	POTASSIUM IODIDE
SUDAFED	PSEUDOEPHEDRINE HCl
SYNTHROID	LEVOTHYROXINE SODIUM
TENUATE	DIETHYLPROPION HCl
TESTOSTERONE	
TUINAL	AMOBARBITAL SODIUM, SECOBARBITAL SODIUM
VASODILAN	ISOXSUPRINE

(PAGES 4127 THROUGH 4132 ARE RESERVED FOR FUTURE USE.)